Preparing Compound Containing At Least Three Carbocyclic Rings Patents (Class 435/127)
  • Patent number: 11680256
    Abstract: A bacterial strain comprising one or more vectors encoding a) one or more enzymes to produce one or more terpene precursors; and b) a fungal terpene synthase (FTPS). The present invention also relates to a method of producing a terpenoid comprising a) culturing the bacterial strain described herein in an expression medium; and b) isolating the terpenoid from said expression medium.
    Type: Grant
    Filed: September 2, 2019
    Date of Patent: June 20, 2023
    Assignees: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH, JUSTUS-LIEBIG-UNIVERSITAET GIESSEN
    Inventors: Congqiang Zhang, Xixian Chen, Ruehl Martin, Heng-Phon Too
  • Patent number: 11332724
    Abstract: The present invention provides genetically engineered host organisms capable of producing terpenoids. The present invention also relates terpenoids obtained from such genetically engineered organisms. Examples of the produced terpenoids include carotenoids, ionones, abienol, and other isoprenoid derived compounds. In addition, the invention relates to a methods of for the preparation of terpenoids using such a genetically engineered organism.
    Type: Grant
    Filed: April 21, 2016
    Date of Patent: May 17, 2022
    Assignee: DSM IP ASSETS B.V.
    Inventors: John Royer, Peter Louis Houston
  • Patent number: 10415071
    Abstract: The present invention provides a method for preparing a steviol glycoside and/or steviol comprising reacting glycosidase AOBGL1 and/or AOBGL3 or a variant thereof with a steviol glycoside having at least one monoglucoside bond and/or monoglucosyl ester bond, thereby cleaving said monoglucoside bond and/or monoglucosyl ester bond.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: September 17, 2019
    Assignee: SUNTORY HOLDINGS LIMITED
    Inventors: Misa Ochiai, Eiichiro Ono
  • Patent number: 9909145
    Abstract: This invention relates generally to methods and compositions for producing a sesquiterpene alcohol comprising contacting a sesquiterpene with a p450 polypeptide with monooxygenase activity.
    Type: Grant
    Filed: September 19, 2014
    Date of Patent: March 6, 2018
    Assignee: FIRMENICH SA
    Inventors: Laurent Daviet, Letizia Rocci, Michel Schalk
  • Publication number: 20150141633
    Abstract: The disclosure relates to a method for enhancing the biosynthesis and/or secretion of sapogenins in the culture medium of plant and microbial cell cultures. Further, the disclosure also relates to the identification of novel genes involved in the biosynthesis of sapogenin intermediates, as well as to novel sapogenin compounds.
    Type: Application
    Filed: May 13, 2013
    Publication date: May 21, 2015
    Inventors: Alain Goossens, Tessa Moses, Jacob Pollier, Lorena Almagro Romero
  • Patent number: 9005939
    Abstract: The present invention relates to an isolated, recombinant or synthetic polynucleotide encoding a polypeptide with protoilludene synthase activity and comprising a sequence selected from the group consisting of a) SEQ ID Nos. 1 or 14 of the attached sequence listing; b) a nucleic acid sequence complementary to SEQ ID Nos. 1 or 14; c) nucleic acid sequences which hybridize under stringent conditions to the nucleic acid sequences defined in a) and b) or their complementary strands, as well as to the polypeptide encoded by the isolated polynucleotide, as well as a method for the production of melleolides employing the polynucleotide or polypeptide of the invention.
    Type: Grant
    Filed: January 31, 2013
    Date of Patent: April 14, 2015
    Assignee: Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.
    Inventors: Stefan Jennewein, Benedikt Engels, Torsten Grothe, Marc Stadler
  • Publication number: 20150099283
    Abstract: A method of producing patchoulol and 7-epi-?-selinene by contacting at least one polypeptide with farnesyl phyrophosphate (fpp). The method may be carried out in vitro or in vivo to produce patchoulol and 7-epi-?-selinene, compounds which can be useful in the field of perfumery.
    Type: Application
    Filed: December 19, 2014
    Publication date: April 9, 2015
    Applicant: FIRMENICH SA
    Inventors: Michel SCHALK, Fabienne DEGUERRY
  • Patent number: 8993269
    Abstract: Glucosyl stevia compositions are prepared from steviol glycosides of Stevia rebaudiana Bertoni. The glucosylation was performed by cyclodextrin glucanotransferase using the starch as source of glucose residues. The short-chain glucosyl stevia compositions were purified to >95% content of total steviol glycosides. The compositions can be used as sweetness enhancers, flavor enhancers and sweeteners in foods, beverages, cosmetics and pharmaceuticals.
    Type: Grant
    Filed: November 6, 2013
    Date of Patent: March 31, 2015
    Assignee: PureCircle USA Inc.
    Inventor: Avetik Markosyan
  • Patent number: 8927238
    Abstract: A method of producing patchoulol and 7-epi-?-selinene by contacting at least one polypeptide with farnesyl phyrophosphate (fpp). The method may be carried out in vitro or in vivo to produce patchoulol and 7-epi-?-selinene, compounds which can be useful in the field of perfumery.
    Type: Grant
    Filed: May 15, 2011
    Date of Patent: January 6, 2015
    Assignee: Firmenich SA
    Inventors: Michel Schalk, Fabienne Deguerry
  • Patent number: 8911971
    Abstract: Glucosyl stevia compositions are prepared from steviol glycosides of Stevia rebaudiana Bertoni. The glucosylation was performed by cyclodextrin glucanotransferase using starch as the source of glucose residues. The short-chain glucosyl stevia compositions were purified to >95% content of total steviol glycosides. The compositions can be used as sweetness enhancers, flavor enhancers and sweeteners in foods, beverages, cosmetics and pharmaceuticals.
    Type: Grant
    Filed: May 4, 2011
    Date of Patent: December 16, 2014
    Assignee: PureCircle USA Inc.
    Inventor: Avetik Markosyan
  • Patent number: 8889381
    Abstract: Provided herein are diterpene synthases (diTPS) and methods for producing diterpenoids. Also provided herein are nucleic acid sequences encoding diTPS, diTPS amino acid sequences, diTPS proteins, vectors, cells, transgenic organisms, uses, compositions, methods, processes, and kits thereof.
    Type: Grant
    Filed: November 21, 2012
    Date of Patent: November 18, 2014
    Assignee: University of British Columbia
    Inventors: Joerg Bohlmann, Philipp Zerbe
  • Publication number: 20140329916
    Abstract: Provided herein is a non-naturally occurring microbial organism having a methanol metabolic pathway that can enhance the availability of reducing equivalents in the presence of methanol. Such reducing equivalents can be used to increase the product yield of organic compounds produced by the microbial organism, such as adipate, 6-aminocaproate, hexamethylenediamine or caprolactam. Also provided herein are methods for using such an organism to produce adipate, 6-aminocaproate, hexamethylenediamine or caprolactam.
    Type: Application
    Filed: December 16, 2013
    Publication date: November 6, 2014
    Applicant: Genomatica, Inc.
    Inventors: Anthony P. Burgard, Robin E. Osterhout, Stephen J. Van Dien, Cara Ann Tracewell, Priti Pharkya, Stefan Andrae
  • Publication number: 20140322768
    Abstract: The present invention relates to isolated polypeptides having peroxygenase activity, and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
    Type: Application
    Filed: November 28, 2012
    Publication date: October 30, 2014
    Inventors: Sara Landvik, Lars Henrik Oestergaard, Lisbeth Kalum
  • Patent number: 8853217
    Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I: wherein the variables are as defined herein.
    Type: Grant
    Filed: September 28, 2012
    Date of Patent: October 7, 2014
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Jean-Damien Charrier, Pierre-Henri Storck, John Studley, Francoise Yvonne Theodora Marie Pierard
  • Patent number: 8846686
    Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; solid forms of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I-1: wherein the variables are as defined herein. Additionally, the compounds of this invention have formula II: or a pharmaceutically acceptable salt thereof, wherein the variables are as defined herein.
    Type: Grant
    Filed: September 28, 2012
    Date of Patent: September 30, 2014
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Jean-Damien Charrier, Pierre-Henri Storck, John Studley, Francoise Yvonne Theodora Marie Pierard, Steven John Durrant, Benjamin Joseph Littler, Paul Angell, Robert Michael Hughes, David Andrew Siesel, Armando Urbina, Carl Zwicker, Nicholas LoConte, Timothy E. Barder
  • Publication number: 20140200201
    Abstract: Provided herein are steroidal compounds that are androsta-5,7-dienes or a pregna-5,7-dienes and ultraviolet B (UVB) conversion products thereof which includes pharmaceutical compositions of the steroidal compounds as shown in Tables 1 and 2. Also provided is a method for producing hydroxylated metabolites of cholecalciferol or ergocalciferol via the P450scc (CYP11A1) or CYP27B1 enzyme systems where the hydroxylase has an activity to hydroxylate position C20 of a secosteroid or its 5,7-dieneal precursor and the hydroxylated metabolites so produced. In addition, a method for inhibiting proliferation of either a normally or abnormally proliferating cell by contacting the cell with any of the compounds described herein. A related method is provided of treating a condition associated with the proliferating cell such as a cancer, a skin disorder, a defect in cell differentiation, cosmetic, prophylaxsis, or healthy cell maintenance.
    Type: Application
    Filed: February 28, 2013
    Publication date: July 17, 2014
    Inventors: Andrzej T. Slominski, Robert C. Tuckey, Blazej Zbytek, Michal A. Zmijewski, Minh Ngoc Nguyen, Zorica Janjetovic, Jianjun Chen, Wei Li, Duane D. Miller, Jordan K. Zjawiony, Arnold E. Postlethwaite, Trevor W. Sweatman
  • Patent number: 8735101
    Abstract: Glucosyl stevia compositions are prepared from steviol glycosides of Stevia rebaudiana Bertoni. The glucosylation was performed by cyclodextrin glucanotransferase using the starch as source of glucose residues. The short-chain glucosyl stevia compositions were purified to >95% content of total steviol glycosides. The compositions can be used as sweetness enhancers, flavor enhancers and sweeteners in foods, beverages, cosmetics and pharmaceuticals.
    Type: Grant
    Filed: August 20, 2012
    Date of Patent: May 27, 2014
    Assignee: PureCircle USA Inc.
    Inventor: Avetik Markosyan
  • Patent number: 8669077
    Abstract: Glucosyl stevia compositions are prepared from steviol glycosides of Stevia rebaudiana Bertoni. The glucosylation was performed by cyclodextrin glucanotransferase using the starch as source of glucose residues. The short-chain glucosyl stevia compositions were purified to >95% content of total steviol glycosides. The compositions can be used as sweetness enhancers, flavor enhancers and sweeteners in foods, beverages, cosmetics and pharmaceuticals.
    Type: Grant
    Filed: October 22, 2012
    Date of Patent: March 11, 2014
    Assignee: PureCircle USA Inc.
    Inventor: Avetik Markosyan
  • Patent number: 8647844
    Abstract: Glucosyl stevia compositions are prepared from steviol glycosides of Stevia rebaudiana Bertoni. The glucosylation was performed by cyclodextrin glucanotransferase using the starch as source of glucose residues. The short-chain glucosyl stevia compositions were purified to >95% content of total steviol glycosides. The compositions can be used as sweetness enhancers, flavor enhancers and sweeteners in foods, beverages, cosmetics and pharmaceuticals.
    Type: Grant
    Filed: August 6, 2012
    Date of Patent: February 11, 2014
    Assignee: PureCircle USA Inc.
    Inventor: Avetik Markosyan
  • Publication number: 20140038246
    Abstract: A method for producing lignin derivatives from technical lignins by treatment with proteolytic enzymes (proteases), characterized in that the proteolytic treatment of the technical lignins significantly reduces the molar mass thereof.
    Type: Application
    Filed: March 2, 2012
    Publication date: February 6, 2014
    Applicant: ANNIKKI GMBH
    Inventors: Ewald Srebotnik, Thomas Ters, Karin Fackler, Kurt Messner, Ortwin Ertl
  • Publication number: 20140024089
    Abstract: The invention relates to recombinant expression of a taxadiene synthase enzyme and a geranylgeranyl diphosphate synthase (GGPPS) enzyme in cells and the production of terpenoids.
    Type: Application
    Filed: July 17, 2013
    Publication date: January 23, 2014
    Applicant: Massachusetts Institute of Technology
    Inventors: PARAYIL K. AJIKUMAR, GREGORY STEPHANOPOULOS, HENG PHON TOO
  • Patent number: 8530205
    Abstract: The present invention relates to a buffer composition for promoting production of calcitriol or calcifediol, and a method for producing calcitriol or calcifediol using the same. More particularly, the present invention relates to a buffer composition for promoting production of calcitriol or calcifediol comprising a metallic compound, an organic solvent, cyclodextrin, tris(hydroxymethyl)aminomethane, sodium succinate, sodium chloride, magnesium chloride, and water, and a method for producing calcitriol or calcifediol using the same. In the method for producing calcitiriol or calcifediol, the production yield of calcitriol or calcifediol is high, and the bioconversion is carried out in an enzyme reaction system instead of in a microorganism culture system. Thus, it is not required to maintain a sterile state. Also, the separation/purification following the completion of a biocatalytic reaction can be carried out in a cleaner state than the microorganism culture method.
    Type: Grant
    Filed: June 16, 2011
    Date of Patent: September 10, 2013
    Assignee: IL Dong Pharm Co., Ltd.
    Inventors: Dae-Jung Kang, Jong-Hyuk Im, Hyun-Jung Jung, Jae-Hoon Kang
  • Publication number: 20130224809
    Abstract: Provided herein are diterpene synthases (diTPS) and methods for producing diterpenoids. Also provided herein are nucleic acid sequences encoding diTPS, diTPS amino acid sequences, diTPS proteins, vectors, cells, transgenic organisms, uses, compositions, methods, processes, and kits thereof.
    Type: Application
    Filed: November 21, 2012
    Publication date: August 29, 2013
    Inventors: Joerg Bohlmann, Philipp Zerbe
  • Publication number: 20130204034
    Abstract: The present invention relates to an isolated, recombinant or synthetic polynucleotide encoding a polypeptide with protoilludene synthase activity and comprising a sequence selected from the group consisting of a) SEQ ID Nos. 1 or 14 of the attached sequence listing; b) a nucleic acid sequence complementary to SEQ ID Nos. 1 or 14; c) nucleic acid sequences which hybridize under stringent conditions to the nucleic acid sequences defined in a) and b) or their complementary strands, as well as to the polypeptide encoded by the isolated polynucleotide, as well as a method for the production of melleolides employing the polynucleotide or polypeptide of the invention.
    Type: Application
    Filed: January 31, 2013
    Publication date: August 8, 2013
    Applicant: Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.
    Inventor: Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.
  • Publication number: 20130171701
    Abstract: The present application, among others, relates to novel polypeptides having diterpene synthase activity, nucleic acid molecules encoding same, as well as to a gene cluster from Clitopilus passeckerianus which is thought to be involved in the biosynthetic pathway for producing pleuromutilin.
    Type: Application
    Filed: March 9, 2011
    Publication date: July 4, 2013
    Inventors: Rudolf Mitterbauer, Thomas Specht
  • Publication number: 20130157307
    Abstract: The invention relates to a process of fermenting plant material in a fermentation medium into a fermentation product using a fermenting organism, wherein one or more deamidases are present in the fermentation medium.
    Type: Application
    Filed: August 2, 2011
    Publication date: June 20, 2013
    Applicants: NOVOZYMES NORTH AMERICA, INC., NOVOZYMES A/S
    Inventors: Chee-Leong Soong, Shiro Fukuyama, Allan Noergaard, Preben Nielsen, Peter Rahbek Oestergaard
  • Publication number: 20130102038
    Abstract: A method of producing patchoulol and 7-epi-?-selinene by contacting at least one polypeptide with farnesyl phyrophosphate (fpp). The method may be carried out in vitro or in vivo to produce patchoulol and 7-epi-?-selinene, compounds which can be useful in the field of perfumery.
    Type: Application
    Filed: May 5, 2011
    Publication date: April 25, 2013
    Applicant: FIRMENICH SA
    Inventors: Michel Schalk, Fabienne Deguerry
  • Publication number: 20130089892
    Abstract: The present invention relates to yeast species which are normally capable of producing sophorolipids but which are modified in such way that they are incapable producing the latter compounds. These sophorolipid-negative strains surprisingly display equal growth characteristics and biomass formation as their wild type counterparts and are hence useful for the production of compounds such as recombinant proteins, glycolipids, polyhydroxyalkanoates and carotenoides. In addition, the present invention discloses two glucosyltransferase genes with key-functions in sophorolipid production.
    Type: Application
    Filed: June 10, 2011
    Publication date: April 11, 2013
    Applicant: Universiteit Gent
    Inventors: Wim Soetaert, Sofie De Maeseneire, Karen Saerens, Sofie Roelants, Inge Van Bogaert
  • Publication number: 20130071887
    Abstract: This invention is directed to a process for cleaving glycoside residues from stevioside to produce steviol using a commercially available enzyme mixture containing pectinase, CYTOLASE PCL5®. In preferred methods, the reaction takes place in the presence of a yeast culture. Also described are combinations of Helix pomatia enzymes and CYTOLASE PCL5®.
    Type: Application
    Filed: January 6, 2011
    Publication date: March 21, 2013
    Applicant: DSM IP ASSETS B.V.
    Inventor: Christof Wehrli
  • Publication number: 20120315672
    Abstract: The invention relates to recombinant expression of terpenoid synthase enzymes and geranylgeranyl diphosphate synthase (GGPPS) enzymes in cells and the production of diterpenoids.
    Type: Application
    Filed: November 10, 2010
    Publication date: December 13, 2012
    Applicant: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Effendi Leonard, Parayil K. Ajikumar, Kristala Lanett Jones Prather, Gregory Stephanopoulos, Kelly Thayer
  • Patent number: 8318459
    Abstract: Glucosyl stevia compositions are prepared from steviol glycosides of Stevia rebaudiana Bertoni. The glucosylation was performed by cyclodextrin glucanotransferase using the starch as source of glucose residues. The short-chain glucosyl stevia compositions were purified to >95 % content of total steviol glycosides. The compositions can be used as sweetness enhancers, flavor enhancers and sweeteners in foods, beverages, cosmetics and pharmaceuticals.
    Type: Grant
    Filed: March 29, 2011
    Date of Patent: November 27, 2012
    Assignee: PureCircle USA
    Inventor: Avetik Markosyan
  • Publication number: 20120258938
    Abstract: Provided herein are steroidal compounds that are androsta-5,7-dienes or pregna-5,7-dienes and ultraviolet B (UVB) conversion products thereof and cholecalciferol derivatives hydroxylated at one or more of C1, C17, C20, C23, C24, C25, and C26 which includes pharmaceutical, cosmeceutical or nutraceutical compositions of the steroidal compounds as shown in Tables 1A, 2A and 3. Also provided is a method for producing hydroxylated metabolites of cholecalciferol via CYP11A1, CYP24, CYP27A1, or CYP27B1 enzyme systems where the hydroxylase has an activity to hydroxylate position C1 or C20 or other position of the sidechain of a secosteroid or its 5,7-dieneal precursor and the hydroxylated metabolites so produced.
    Type: Application
    Filed: April 30, 2012
    Publication date: October 11, 2012
    Inventors: Andrej Slominski, Robert C. Tuckey, Edith Tang, Elaine Tieu, Minh Nguyen, Zorica Janjetovic, Jianjun Chen, Wei Li, Yan Lu, Duane D. Miller, Jordan K. Zjawiony, Arnold E. Postlethwaite
  • Publication number: 20120246760
    Abstract: Identification of a protein having an activity of oxidizing oleanane-type triterpene, and a gene encoding the protein, the protein and the gene, and use thereof are provided. For example, a protein having an activity of oxidizing oleanane-type triterpene obtained from a plant in the family Fabaceae, a gene encoding the protein and use thereof are provided. The protein is shown in, for example, SEQ ID NO: 4, 14 or 18, and the gene encoding the protein is shown in, for example, SEQ ID NO: 3, 13 or 17. A transformant into which the gene is introduced can be produced, and thereby a triterpene oxidase can be obtained.
    Type: Application
    Filed: August 31, 2009
    Publication date: September 27, 2012
    Applicant: RIKEN
    Inventors: Toshiya Muranaka, Hikaru Seki, Kiyoshi Ohyama, Hiroshi Sudo, Satoru Sawai, Kazuki Saito
  • Patent number: 8273708
    Abstract: The invention concerns compositions and methods for treating and/or preventing ocular pathologies. The invention also concerns compositions and methods enabling the regulation of paracellular permeability of the ocular epithelium. The compositions and methods of the invention are based in particular on the use of agents or conditions modulating the opening of tight junctions of the ocular epithelium. The invention can be used for preventive or curative treatment of various pathologies, such as pathologies of the ocular surface in mammals, particularly in human beings.
    Type: Grant
    Filed: December 9, 2005
    Date of Patent: September 25, 2012
    Inventors: Lionel Bueno, Marie-Thérése Droy-Lefaix, Philippe Caron
  • Patent number: 8257948
    Abstract: Glucosyl stevia compositions are prepared from steviol glycosides of Stevia rebaudiana Bertoni. The glucosylation was performed by cyclodextrin glucanotransferase using the starch as source of glucose residues. The short-chain glucosyl stevia compositions were purified to >95% content of total steviol glycosides. The compositions can be used as sweetness enhancers, flavor enhancers and sweeteners in foods, beverages, cosmetics and pharmaceuticals.
    Type: Grant
    Filed: February 17, 2011
    Date of Patent: September 4, 2012
    Assignee: PureCircle USA
    Inventor: Avetik Markosyan
  • Publication number: 20120142047
    Abstract: An assembly capable of capturing and purifying expressed biological products during or at the end of a bioreaction cycle is disclosed wherein a binding resin is kept separated from the contents of the bioreactor allowing capturing, harvesting and purification of biological products in a bioreactor; the invention additionally provides means of removing undesirable metabolic products as well as provides for efficient loading of chromatography columns.
    Type: Application
    Filed: November 29, 2011
    Publication date: June 7, 2012
    Applicant: Therapeutic Proteins, Inc.
    Inventor: Sarfaraz K. Niazi
  • Publication number: 20120129927
    Abstract: The invention relates to two novel substances, namely (1R,2S,3S,4R)-3-acetoxy-1,2,4,5-tetrahydroxy-7-methoxy-2-methyl-1,2,3,4-tetrahydroanthracene-9,10-dione (3-O-acetyl altersolanol M) and 8-(4,5,6-trihydroxy-7-methyl-2-methoxy-9,10-dioxo-9H,10H-anthracen-1-yl)-(1S,2S,3R,4S)-1,2,3,4,5-pentahydroxy-7-methoxy-2-methyl-1,2,3,4-tetrahydro-9H,10H-anthracene-9,10-dione (the atropisomers alterporriol I and J) to their use as anti-infectives and as anti-cancer agents, as well as to methods of producing the same.
    Type: Application
    Filed: May 31, 2010
    Publication date: May 24, 2012
    Applicant: SEALIFE PHARMA GMBH
    Inventors: Alexander Pretsch, Peter Proksch, Abdessamad Debbab
  • Publication number: 20120129949
    Abstract: The present invention relates to the use of the following anthracene derivatives as anti-infectives, preferably against multiply drug resistant pathogens: (2R,3S,10R)-2,3,5,10-tetrahydroxy-6-methoxy-3-methyl-1,2,3,4,4a,9a-hexahydro-9H,10H-anthracen-9-one (tetrahydroaltersolanol B), (1R,2R,3R,4aS,9aR,10R)-1,2,3,5,10-pentahydroxy-7-methoxy-2-methyl-1,2,3,4,4a,9a-hexahydro-9H,10H-anthracen-9-one (altersolanol K), (2R,3R,4R,4aS,9aS,10R)-2,3,4,8,10-pentahydroxy-6-methoxy-3-methyl-1,2,3,4,4a,9a-hexahydro-9H,10H-anthracen-9-one (altersolanol L), 8-(1,7-dihydroxy-6-methyl-3-methoxy-9,10-dioxo-9H,10H-anthracen-2-yl)-(1S,2S,3R,4S)-1,2,3,4,5-pentahydroxy-7-methoxy-2-methyl-1,2,3,4-tetrahydro-9H,10H-anthracen-9,10-dione (atropisomers alterporriol G and H); as well as (2R,3S,4aS,9aS,10R)-2,3,5,8,10-pentahydroxy-6-methoxy-3-methyl-1,2,3,4,4a,9a-hexahydro-9H,10H-anthracen-9-one (8-hydroxytetrahydroaltersolanol B).
    Type: Application
    Filed: May 31, 2010
    Publication date: May 24, 2012
    Applicant: SEALIFE PHARMA GMBH
    Inventors: Alexander Pretsch, Peter Proksch, Abdessamad Debbab
  • Patent number: 8148119
    Abstract: A vitamin D3 hydroxylase is purified from Pseudonocardia autotrophica cell, and a primer is designed based on amino acid sequence obtained from hydroxylase. Subsequently, PCR is conducted using genomic DNA of Pseudonocardia autotrophica as a template to clone a gene for the vitamin D3 hydroxylase. By conducting a conversion reaction using a microorganism in which the vitamin D3 hydroxylase gene is expressed using a proper expression system, a hydroxide of vitamin D or the like (e.g., hydroxy vitamin D3) can be produced with high efficiency.
    Type: Grant
    Filed: May 18, 2007
    Date of Patent: April 3, 2012
    Assignees: Microbiopharm Japan Co., Ltd., National Institute of Advanced Industrial Science and Technology
    Inventors: Yoshikazu Fujii, Tomohiro Tamura
  • Publication number: 20120064584
    Abstract: The present invention relates to a buffer composition for promoting production of calcitriol or calcifediol, and a method for producing calcitriol or calcifediol using the same. More particularly, the present invention relates to a buffer composition for promoting production of calcitriol or calcifediol comprising a metallic compound, an organic solvent, cyclodextrin, tris(hydroxymethyl)aminomethane, sodium succinate, sodium chloride, magnesium chloride, and water, and a method for producing calcitriol or calcifediol using the same. In the method for producing calcitiriol or calcifediol, the production yield of calcitriol or calcifediol is high, and the bioconversion is carried out in an enzyme reaction system instead of in a microorganism culture system. Thus, it is not required to maintain a sterile state. Also, the separation/purification following the completion of a biocatalytic reaction can be carried out in a cleaner state than the microorganism culture method.
    Type: Application
    Filed: June 16, 2011
    Publication date: March 15, 2012
    Applicant: ILDONG PHARM CO., LTD.
    Inventors: Dae-Jung Kang, Jong-Hyuk Im, Hyun-Jung Jung, Jae-Hoon Kang
  • Publication number: 20110287476
    Abstract: The present invention provides methods for a robust production of isoprenoids via one or more biosynthetic pathways. The invention also provides nucleic acids, enzymes, expression vectors, and genetically modified host cells for carrying out the subject methods. The invention also provides fermentation methods for high productivity of isoprenoids from genetically modified host cells.
    Type: Application
    Filed: December 15, 2009
    Publication date: November 24, 2011
    Inventors: Neil Stephen Renninger, Jack Newman, Keith Kinkead Reiling, Rika Regentin, Christopher John Paddon
  • Publication number: 20110262978
    Abstract: An expression vector capable of expressing a foreign gene in Pseudonocardia autotrophica; a transformant of Pseudonocardia autotrophica produced by using the expression vector; a method for producing a protein by using the transformant; a method for producing an active form of vitamin D3 from vitamin D3, which comprises highly expressing a gene encoding an enzyme involved in the synthesis of the active form of vitamin D3 in a transformant by using the expression vector or the transformant; a method for producing 25-hydroxyvitamin D2 from vitamin D2; and a method for producing pravastatin from compactin, which comprises highly expressing a compactin hydroxylase gene in a transformant by using the expression vector or the transformant.
    Type: Application
    Filed: October 5, 2009
    Publication date: October 27, 2011
    Applicant: MERCIAN CORPORATION
    Inventors: Yoshikazu Fujii, Tadashi Fujii, Akira Arisawa, Tomohiro Tamura
  • Publication number: 20110207705
    Abstract: Oviedomycin derivatives, method for obtaining same and use thereof. This invention relates to oviedomycin derivatives obtained by fermentation of recombinant bacterial strains. The invention also relates to the methods used to obtain the recombinant strains and to produce the oviedomycin derivatives. The invention further relates to bacterial strains that can be used to produce oviedomycin derivatives. Finally, said oviedomycin derivatives are applicable in the field of the human health, specifically to produce drugs for the treatment of tumour diseases.
    Type: Application
    Filed: March 26, 2009
    Publication date: August 25, 2011
    Applicant: UNIVERSIDAD DE OVIEDO
    Inventors: Carmen Méndez Fernández, Felipe Lombó Brugos, Alfredo A. Fernández Braña, José Antonio Salas Fernández
  • Publication number: 20110171698
    Abstract: ?-Amyrin, a precursor in biosynthesis of soyasapogenol B, is biosynthesized by cyclization of 2,3-oxidosqualene which is generated by the mevalonate pathway, and soyasapogenol B is biosynthesized by two hydroxylations of ?-amyrin. However, a gene of 22-hydroxylase involved in the sequence of reactions has not been identified. The present inventors identified a gene encoding the hydroxylase for oleanene triterpenes at C-22, and found that oleanene triterpenes could be hydroxylated at C-22 by co-expressing this gene together with one or more specific genes. Further, the present inventors found that soyasapogenol B could be efficiently produced in large quantities by co-expressing this gene for 22-hydroxylase with a gene for 24-hydroxylase.
    Type: Application
    Filed: January 20, 2010
    Publication date: July 14, 2011
    Applicant: MEIJI SEIKA KAISHA, LTD.
    Inventors: Yutaka Ebizuka, Masaaki Shibuya, Eriko Wakita
  • Patent number: 7972821
    Abstract: A method for the production of functional proteins including hormones by renal cells in a three dimensional culturing process responsive to shear stress uses a rotating wall vessel. Natural mixture of renal cells expresses the enzyme 1-?-hydroxylase which can be used to generate the active form of vitamin D: 1,25-diOH vitamin D3. The fibroblast cultures and co-culture of renal cortical cells express the gene for erythropoietin and secrete erythropoietin into the culture supernatant. Other shear stress response genes are also modulated by shear stress, such as toxin receptors megalin and cubulin (gp280). Also provided is a method of treating an in-need individual with the functional proteins produced in a three dimensional co-culture process responsive to shear stress using a rotating wall vessel.
    Type: Grant
    Filed: July 16, 2008
    Date of Patent: July 5, 2011
    Assignee: The United States of America as represented by the Administrator of the National Aeronautics and Space Administration
    Inventors: Thomas John Goodwin, Timothy Grant Hammond, James Howard Kaysen
  • Patent number: 7910334
    Abstract: The present invention relates to a biotransformation process, effected by means of selected microbial strains, for the preparation of 3-O-glycosyl derivatives of colchicinoid compounds.
    Type: Grant
    Filed: May 12, 2004
    Date of Patent: March 22, 2011
    Assignee: Indena S.p.A.
    Inventor: Cesare Ponzone
  • Publication number: 20100297712
    Abstract: A vitamin D3 hydroxylase is purified from Pseudonocardia autotrophica cell, and a primer is designed based on amino acid sequence obtained from hydroxylase. Subsequently, PCR is conducted using genomic DNA of Pseudonocardia autotrophica as a template to clone a gene for the vitamin D3 hydroxylase. By conducting a conversion reaction using a microorganism in which the vitamin D3 hydroxylase gene is expressed using a proper expression system, a hydroxide of vitamin D or the like (e.g., hydroxy vitamin D3) can be produced with high efficiency.
    Type: Application
    Filed: May 15, 2007
    Publication date: November 25, 2010
    Applicants: MERCIAN CORPORATION, National Institute of Advanced Industrial Science Technology
    Inventors: Yoshikazu Fujii, Tomohiro TAMURA
  • Publication number: 20100240746
    Abstract: Provided herein are optically active stereoisomers of tricylclodecan-9-yl xanthogenate, processes of preparation, and pharmaceutical compositions thereof. Also provided are methods of their use for treating, preventing, or ameliorating one or more symptoms of a disease caused by a virus.
    Type: Application
    Filed: July 3, 2008
    Publication date: September 23, 2010
    Applicant: LUMAVITA AG
    Inventors: Miyuki Tomioka, Ko Hasegawa
  • Patent number: 7790425
    Abstract: The present invention provides a protein having saponin-decomposing activity, more specifically a protein which can decompose a glycoside having soyasapogenol B as an aglycone to produce soyasapogenol B, a polynucleotide encoding such a protein, and a method of producing soyasapogenol B on a large scale using the same. A protein according to the present invention are concerned with (a), (b) or (c), namely (a) a protein comprising an amino acid sequence selected from the group consisting of the amino acid sequences shown in SEQ ID NOs: 2, 4, and 6; (b) a protein that has at least 50% homology to the protein comprising the amino acid sequence of the sequence described in (a) and having saponin-decomposing activity; or (c) a protein comprising a modified amino acid sequence of the sequence described in (a) that has one or more amino acid residues deleted, substituted, inserted, or added and having saponin-decomposing activity.
    Type: Grant
    Filed: November 24, 2009
    Date of Patent: September 7, 2010
    Assignee: Meiji Seika Kaisha, Ltd.
    Inventors: Manabu Watanabe, Naoki Mido, Takayoshi Tamura, Naomi Sumida, Takashi Yaguchi
  • Publication number: 20100035310
    Abstract: A method for the production of functional proteins including hormones by renal cells in a three dimensional culturing process responsive to shear stress uses a rotating wall vessel. Natural mixture of renal cells expresses the enzyme 1-?-hydroxylase which can be used to generate the active form of vitamin D: 1,25-diOH vitamin D3. The fibroblast cultures and co-culture of renal cortical cells express the gene for erythropoietin and secrete erythropoietin into the culture supernatant. Other shear stress response genes are also modulated by shear stress, such as toxin receptors megalin and cubulin (gp280). Also provided is a method of treating an in-need individual with the functional proteins produced in a three dimensional co-culture process responsive to shear stress using a rotating wall vessel.
    Type: Application
    Filed: July 16, 2008
    Publication date: February 11, 2010
    Inventors: Thomas John Goodwin, Timothy Grant Hammond, James Howard Kaysen